<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04400591</url>
  </required_header>
  <id_info>
    <org_study_id>JCAR017-EAP-001</org_study_id>
    <secondary_id>U1111-1251-6894</secondary_id>
    <nct_id>NCT04400591</nct_id>
  </id_info>
  <brief_title>Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol</brief_title>
  <official_title>Expanded Access Protocol (EAP) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That is Out of Specification (OOS) for Commercial Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juno Therapeutics, a Subsidiary of Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juno Therapeutics, a Subsidiary of Celgene</source>
  <brief_summary>
    <textblock>
      This is an expanded access protocol that will be conducted at sites qualified and approved to&#xD;
      treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is&#xD;
      manufactured the drug does not pass all the testing results to be called lisocabtagene&#xD;
      maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The&#xD;
      expanded access protocol will be used to allow subjects to receive nonconforming&#xD;
      lisocabtagene maraleucel only if the potential benefit is better than the potential risk.&#xD;
      This expanded access protocol is restricted to those subjects who were prescribed&#xD;
      lisocabtagene maraleucel as part of their routine care.&#xD;
&#xD;
      Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with&#xD;
      nonconforming lisocabtagene maraleucel as the treatment plan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nonconforming Lisocabtagene Maraleucel</intervention_name>
    <description>Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.</description>
    <other_name>JCAR017</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject and/or LAR must understand and voluntarily sign an informed consent form prior&#xD;
             to any study-related assessments/procedures being conducted.&#xD;
&#xD;
          2. Subject has relapsed and/or refractory large B-cell lymphoma and is, per the treating&#xD;
             physician assessment, eligible for treatment with lisocabtagene maraleucel per the&#xD;
             approved prescribing information.&#xD;
&#xD;
          3. Subject is ≥ 18 years of age at the time of signing the informed consent form.&#xD;
&#xD;
          4. Subject had a specific batch of lisocabtagene maraleucel manufactured intended for&#xD;
             commercial treatment; however, the final manufactured product did not meet commercial&#xD;
             release criteria.&#xD;
&#xD;
          5. Remanufacturing (eg, repeat leukapheresis and manufacturing) is deemed not feasible or&#xD;
             clinically inappropriate per assessment of the treating physician in discussion with&#xD;
             the subject.&#xD;
&#xD;
          6. Subject is clinically stable, has recovered from any toxicities prior to receiving&#xD;
             lymphodepleting chemotherapy, and has adequate bone marrow function to receive&#xD;
             lymphodepleting chemotherapy. The treating physician is advised to contact Medical&#xD;
             Monitor in the event there is any concern regarding administration of lymphodepleting&#xD;
             chemotherapy.&#xD;
&#xD;
          7. Females of childbearing potential must:&#xD;
&#xD;
               1. Have a negative pregnancy test as verified by the treating physician within 7&#xD;
                  days prior to the first dose of lymphodepleting chemotherapy following&#xD;
                  institutional testing methodology practices. This applies even if the subject&#xD;
                  practices true abstinence from heterosexual contact.&#xD;
&#xD;
               2. Either commit to true abstinence from heterosexual contact or agree to use, and&#xD;
                  be able to comply with, effective contraception without interruption.&#xD;
                  Contraception methods must include 1 highly effective method from screening until&#xD;
                  at least 12 months after the nonconforming lisocabtagene maraleucel&#xD;
                  administration.&#xD;
&#xD;
               3. Agree to abstain from breastfeeding during study participation and for at least&#xD;
                  12 months following nonconforming lisocabtagene maraleucel administration.&#xD;
&#xD;
               4. There are insufficient exposure data to provide any recommendation concerning the&#xD;
                  duration of contraception and the abstaining from breastfeeding following&#xD;
                  treatment with lisocabtagene maraleucel. Any decision regarding contraception and&#xD;
                  breastfeeding after infusion should be discussed with the treating physician.&#xD;
&#xD;
          8. Male subjects must:&#xD;
&#xD;
               1. Practice true abstinence or agree to use a condom during sexual contact with a&#xD;
                  pregnant female or a female of childbearing potential for at least 12 months&#xD;
                  after nonconforming lisocabtagene maraleucel administration even if the subject&#xD;
                  has undergone a successful vasectomy.&#xD;
&#xD;
               2. There are insufficient exposure data to provide any recommendation concerning the&#xD;
                  duration of contraception following treatment with lisocabtagene maraleucel. Any&#xD;
                  decision regarding contraception after infusion should be discussed with the&#xD;
                  treating physician&#xD;
&#xD;
          9. Subject must agree to not donate blood, organs, tissue, sperm or semen and egg cells&#xD;
             for usage in other individuals for at least 1 year following nonconforming&#xD;
             lisocabtagene maraleucel administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a hypersensitivity to the active substance or to any of the excipients.&#xD;
&#xD;
          2. Subject should not experience a significant worsening in clinical status that would,&#xD;
             in the opinion of the treating physician, either increase the risk of adverse events&#xD;
             associated with lymphodepleting chemotherapy, or exclude them from treatment with&#xD;
             nonconforming lisocabtagene maraleucel.&#xD;
&#xD;
          3. Subject has any significant medical condition, laboratory abnormality, or psychiatric&#xD;
             illness, sociologic or geographic condition that would prevent the subject from&#xD;
             participating in the Expanded Access Protocol complying with protocol requirements in&#xD;
             the Investigator's judgement.&#xD;
&#xD;
          4. Subject has any condition and/or laboratory abnormality that places the subject at&#xD;
             unacceptable risk if he/she were to participate in the Expanded Access Protocol based&#xD;
             on the Investigator's judgement&#xD;
&#xD;
          5. Pregnant or nursing women or has intention of becoming pregnant during the study.&#xD;
&#xD;
          6. Subjects with central nervous system (CNS)-only involvement by malignancy (note:&#xD;
             subjects with secondary CNS involvement are allowed on study).&#xD;
&#xD;
          7. Subject has active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xD;
             infection at the time of pretreatment evaluation&#xD;
&#xD;
          8. Subject has uncontrolled systemic fungal, bacterial, viral or other infection despite&#xD;
             appropriate antibiotics or other treatment at the time of nonconforming lisocabtagene&#xD;
             maraleucel administration.&#xD;
&#xD;
          9. Subject has presence of acute or chronic graft-versus-host disease (ie, GVHD)&#xD;
&#xD;
         10. Use of the following:&#xD;
&#xD;
               1. Therapeutic doses of corticosteroids (defined as &gt; 20 mg/day prednisone or&#xD;
                  equivalent) within 72 hours prior to nonconforming lisocabtagene maraleucel&#xD;
                  administration. Physiologic replacement, topical, and inhaled steroids are&#xD;
                  permitted.&#xD;
&#xD;
               2. Low dose chemotherapy (eg, vincristine, rituximab, cyclophosphamide ≤ 300&#xD;
                  mg/m2)given after leukapheresis to maintain disease control must be stopped ≥ 7&#xD;
                  days prior to lymphodepleting chemotherapy.&#xD;
&#xD;
               3. Cytotoxic chemotherapeutic agents that are not considered lymphotoxic (see below)&#xD;
                  within 1 week of LD chemotherapy. Oral chemotherapeutic agents, including&#xD;
                  lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed&#xD;
                  prior to lymphodepleting chemotherapy.&#xD;
&#xD;
               4. Donor lymphocyte infusions within 6 weeks of nonconforming lisocabtagene&#xD;
                  maraleucel administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BMS Study Connect Contact Center www.BMSStudyConnect.com</last_name>
    <phone>855-907-3286</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site #.</last_name>
  </overall_contact_backup>
  <removed_countries>
    <country>Japan</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>May 20, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>April 29, 2022</last_update_submitted>
  <last_update_submitted_qc>April 29, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>JCAR017</keyword>
  <keyword>Lisocabtagene Maraleucel</keyword>
  <keyword>CAR T</keyword>
  <keyword>nonconforming;</keyword>
  <keyword>relapsed/refractory diffuse large B cell lymphoma</keyword>
  <keyword>nonconforming lisocabtagene mareleucel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04400591
org study id: JCAR017-EAP-001
secondary id: U1111-1251-6894
nct id: NCT04400591
lead sponsor: 
This is an expanded access protocol that will be conducted at sites qualified and approved to
      treat subjects with lisocabtagene maraleucel. Sometimes when lisocabtagene maraleucel is
      manufactured the drug does not pass all the testing results to be called lisocabtagene
      maraleucel. When this happens the drug is called nonconforming lisocabtagene maraleucel. The
      expanded access protocol will be used to allow subjects to receive nonconforming
      lisocabtagene maraleucel only if the potential benefit is better than the potential risk.
      This expanded access protocol is restricted to those subjects who were prescribed
      lisocabtagene maraleucel as part of their routine care.

      Subjects will first receive a lymphodepleting chemotherapy regimen and then be treated with
      nonconforming lisocabtagene maraleucel as the treatment plan.
expanded access type intermediate: Yes
intervention type: Biological
intervention name: Nonconforming Lisocabtagene Maraleucel
description: Nonconforming lisocabtagene maraleucel is lisocabtagene maraleucel that does not meet the commercial release specifications, however is deemed acceptable to administer as an investigational product in the Expanded Access Protocol setting.
other name: JCAR017
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
last name: Bristol-Myers Squibb
role: Study Director
affiliation: Bristol-Myers Squibb
last name: BMS Study Connect Contact Center www.BMSStudyConnect.com
phone: 855-907-3286
email: Clinical.Trials@bms.com
last name: First line of the email MUST contain the NCT# and Site #.
country: Japan
country: United States
responsible party type: Sponsor
mesh term: Lymphoma, Large B-Cell, Diffuse